<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02973776</url>
  </required_header>
  <id_info>
    <org_study_id>LP0053-1276</org_study_id>
    <nct_id>NCT02973776</nct_id>
  </id_info>
  <brief_title>Vasoconstriction Trial With LEO 90100 Aerosol Foam</brief_title>
  <official_title>Vasoconstriction Trial Comparing LEO 90100 With Dermovate Cream, Diprosone Ointment, Elocon Cream, Locoid Ointment and LEO 90100 Vehicle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoconstriction study with LEO 90100
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares the pharmacodynamic activity of LEO 90100 with Dermovate cream, Diprosone
      ointment, Elocon cream, Locoid ointment and LEO 90100 vehicle using a human skin blanching
      test
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean of two visual skin blanching scores for each treatment measured 2 hours after 16 hours application under non-occlusive conditions</measure>
    <time_frame>18 hours</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermoval®/Dermovate®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diprosone®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elocon®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elocon® mometasone furoate 0.1% cream
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Locoid®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Locoid® hydrocortisone-17-butyrate 0.1% ointment
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 90100 foam vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LEO 90100 foam vehicle
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 aerosol foam</intervention_name>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_label>Dermoval®/Dermovate®</arm_group_label>
    <arm_group_label>Diprosone®</arm_group_label>
    <arm_group_label>Elocon®</arm_group_label>
    <arm_group_label>Locoid®</arm_group_label>
    <arm_group_label>LEO 90100 foam vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dermoval®/Dermovate®</intervention_name>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_label>Dermoval®/Dermovate®</arm_group_label>
    <arm_group_label>Diprosone®</arm_group_label>
    <arm_group_label>Elocon®</arm_group_label>
    <arm_group_label>Locoid®</arm_group_label>
    <arm_group_label>LEO 90100 foam vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprosone</intervention_name>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_label>Dermoval®/Dermovate®</arm_group_label>
    <arm_group_label>Diprosone®</arm_group_label>
    <arm_group_label>Elocon®</arm_group_label>
    <arm_group_label>Locoid®</arm_group_label>
    <arm_group_label>LEO 90100 foam vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elocon</intervention_name>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_label>Dermoval®/Dermovate®</arm_group_label>
    <arm_group_label>Diprosone®</arm_group_label>
    <arm_group_label>Elocon®</arm_group_label>
    <arm_group_label>Locoid®</arm_group_label>
    <arm_group_label>LEO 90100 foam vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Locoid</intervention_name>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_label>Dermoval®/Dermovate®</arm_group_label>
    <arm_group_label>Diprosone®</arm_group_label>
    <arm_group_label>Elocon®</arm_group_label>
    <arm_group_label>Locoid®</arm_group_label>
    <arm_group_label>LEO 90100 foam vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LEO 90100 foam vehicle</intervention_name>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_label>Dermoval®/Dermovate®</arm_group_label>
    <arm_group_label>Diprosone®</arm_group_label>
    <arm_group_label>Elocon®</arm_group_label>
    <arm_group_label>Locoid®</arm_group_label>
    <arm_group_label>LEO 90100 foam vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects demonstrating adequate vasoconstriction to Diprosone® ointment within 15 days
             prior to dosing (unoccluded application of Diprosone® ointment for 4-6 hours must show
             a visual score of skin blanching of at least one unit (visual scale (0-4)).

          -  Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on
             test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn).

        Exclusion Criteria:

          -  Abnormal pigmentation of the skin or skin type that could, in any way, confound
             interpretation of the trial results (skin type V and VI on the Fitzpatrick scale).

          -  Female subjects who are breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CPCAD</name>
      <address>
        <city>Nice</city>
        <state>Cedex</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone-17-butyrate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

